Formate → HCID 178520650, Verbindung

HRID 1695241

Reaktionsgleichung

Reaktionsgleichung von HRID 1695241
[CH:1]1([CH2:4][O:5][C:6]2[CH:11]=[CH:10][C:9]([C:12]3[CH:13]=[C:14]([NH2:17])[NH:15][N:16]=3)=[CH:8][CH:7]=2)[CH2:3][CH2:2]1.[N:18]1([CH2:24][CH2:25][CH2:26][C:27](O)=[O:28])[CH2:23][CH2:22][CH2:21][CH2:20][CH2:19]1.C([O-])=O>>[CH:1]1([CH2:4][O:5][C:6]2[CH:7]=[CH:8][C:9]([C:12]3[CH:13]=[C:14]([NH:17][C:27](=[O:28])[CH2:26][CH2:25][CH2:24][N:18]4[CH2:23][CH2:22][CH2:21][CH2:20][CH2:19]4)[NH:15][N:16]=3)=[CH:10][CH:11]=2)[CH2:2][CH2:3]1

Komponenten

4

Edukt 3

HCID 283FormateHCID 20794Butyric acid, 4-piperidino-HCID 178507293HCID 178507293, Verbindung

Produkt 1

HCID 178520650HCID 178520650, VerbindungAusbeute 28 %

Versuchsvorschrift

The product was prepared according to the general synthetic method for the synthesis of ω-amino-alkanoic acid (1H-pyrazol-3-yl-5-aryl)-amides via the amino acid route, starting from 5-(4-cyclopropylmethoxy-phenyl)-2H-pyrazol-3-ylamine (152.9 mg, 0.7 mmol, 1.0 eq) and 4-piperidin-1-yl-butyric acid (168 mg, 1.0 mmol, 1.5 eq). The crude product was purified via preparative HPLC; 72.0 mg of the title product (28% yield) was obtained as a formate salt.

Aufarbeitung

  1. customThe product was prepared
  2. customThe crude product was purified via preparative HPLC

Quellen und Nachweise

ORD-Eintrag
ord-72fb51b6e0614cacb579e72814fe1012
Quelldatensatz
uspto-grants-2012_04
Patentnummer
US08163729B2

Verknüpfte Notizen

Wird geladen…